文献速递外周动脉疾病

比较慢性肢体威胁性缺血患者初次血管内治疗后再狭窄的踝下旁路手术与重复血管内治疗的疗效

Comparison of Subsequent Inframalleolar Bypass Surgery and Repeat Endovascular Therapy for Infrapopliteal Restenosis in Patients With Chronic Limb-Threatening Ischemia Undergoing Primary Endovascular Therapy.
PubMed 文献 · J Endovasc Ther · 2024-08-01

本研究回顾性分析140例慢性肢体威胁性缺血(CLTI)伴踝下病变再狭窄且创面未愈合的患者,比较后续踝下旁路手术(40例)与重复血管内治疗(100例)的临床结局。倾向性评分匹配后,两组无截肢生存率和累积创面愈合率均无显著差异。

要点

  • 匹配后重复血管内治疗组与后续旁路手术组1年无截肢生存率分别为81.9%和82.6%,无显著差异(p=0.97)。
  • 匹配后两组1年累积创面愈合率分别为42.8%和43.3%,无显著差异(p=0.55)。
  • 重复血管内治疗可能是CLTI伴踝下病变再狭窄的一种可行治疗选择。

核心结论

  • 倾向性评分匹配分析显示,重复血管内治疗与后续踝下旁路手术治疗CLTI伴踝下病变再狭窄的临床结局相当,重复血管内治疗可能是可行治疗选择。

研究设计与样本

  • 回顾性分析2015年1月至2020年5月间140例因踝下病变再狭窄导致创面未愈合的CLTI患者,平均年龄70±10岁,男性71.4%,糖尿病73.6%,透析74.3%,Rutherford 5级79.3%,Rutherford 6级20.7%。
  • 比较后续踝下旁路手术组40例与重复血管内治疗组100例的临床结局,采用倾向性评分匹配分析以减少基线特征差异。
  • 匹配后提取38对(后续旁路手术组38例,重复血管内治疗组83例)。

主要发现

  • 匹配后重复血管内治疗组与后续旁路手术组1年无截肢生存率分别为81.9%和82.6%,无显著差异(p=0.97)。
  • 匹配后重复血管内治疗组与后续旁路手术组1年累积创面愈合率分别为42.8%和43.3%,无显著差异(p=0.55)。
  • 无基线特征对重复血管内治疗、后续旁路手术与无截肢生存失败之间的关联有显著交互作用。

临床怎么用

  • 作者认为,重复血管内治疗可能是CLTI伴踝下病变再狭窄的可行治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although endovascular therapy (EVT) is considered a vital strategy for treating infrapopliteal lesions in chronic limb-threatening ischemia (CLTI), the recurrence rate after EVT exceeds that after bypass surgery (BSX). The optimal approach for managing infrapopliteal lesion recurrence in patients with CLTI and unhealed ulcers remains uncertain. This study aimed to evaluate the clinical outcomes of repeat EVT and subsequent inframalleolar BSX for CLTI with infrapopliteal lesion recurrence. MATERIALS AND METHODS: We conducted a retrospective analysis of 140 patients with CLTI (mean age, 70±10 years; male, 71.4%; diabetes mellitus, 73.6%; dialysis, 74.3%; Rutherford 5, 79.3%; and Rutherford 6, 20.7%) who had an unhealed wound due to the recurrence of infrapopliteal lesions between January 2015 and May 2020. We compared the clinical outcomes of 40 patients who underwent the subsequent inframalleolar BSX with those of 100 patients who underwent repeat EVT. The outcome measures were amputation-free survival (AFS) and wound healing rate. Propensity score matching analysis was conducted to minimize differences in baseline characteristics. RESULTS: Propensity score matching extracted 38 pairs (38 patients in the subsequent BSX group and 83 patients in the repeat EVT group). AFS was not significantly different between the repeat EVT and subsequent BSX groups (81.9% vs 82.6% at 1 year, p=0.97). Neither was cumulative wound healing (42.8% vs 43.3% at 1 year, p=0.55). No baseline characteristics had any significant interaction effect on the association between repeat EVT, subsequent BSX, and failure of AFS. CONCLUSION: This study using propensity score matching revealed that the clinical outcomes following repeat EVT were comparable with those following subsequent inframalleolar BSX, indicating that repeat EVT may be a viable treatment option for CLTI with infrapopliteal lesion recurrence.Clinical ImpactAlthough endovascular therapy (EVT) has expanded the treatment options for chronic limb-threatening ischemia (CLTI), the recurrence rate after EVT is higher than that after bypass surgery (BSX). This retrospective study compared the clinical outcomes of repeat EVT with those of subsequent BSX for CLTI with infrapopliteal lesion recurrence. After propensity score matching, amputation-free survival (AFS) was not significantly different between the repeat EVT and subsequent BSX groups (81.9% vs 82.6% at 1 year, p=0.97). Neither was cumulative wound healing (42.8% vs 43.3% at 1 year, p=0.55). There was no difference between the 2 revascularization strategies when treating infrapopliteal restenosis lesions.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Suzuki R, Horiuchi K, Iida O, et al. Comparison of Subsequent Inframalleolar Bypass Surgery and Repeat Endovascular Therapy for Infrapopliteal Restenosis in Patients With Chronic Limb-Threatening Ischemia Undergoing Primary Endovascular Therapy. J Endovasc Ther. 2024. PMID: 39091096. doi:10.1177/15266028241267735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。